Absci Corporation (ABSI)

Market Cap	308.39M
Revenue (ttm)	4.21M
Net Income (ttm)	-97.67M
Shares Out	114.86M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,973
Open	2.740
Previous Close	2.770
Day's Range	2.620 - 2.770
52-Week Range	2.450 - 6.720
Beta	2.03
Analysts	Strong Buy
Price Target	8.67 (+222.91%)
Earnings Date	Nov 12, 2024

About ABSI

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 22, 2021
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: ABSI
• Website: https://www.absci.com

Financial Performance

In 2023, Absci's revenue was $5.72 million, a decrease of -0.50% compared to the previous year's $5.75 million. Losses were -$110.57 million, 5.40% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $8.67, which is an increase of 222.91% from the latest price.

Price Target

$8.67

(222.91% upside)

Analyst Consensus: Strong Buy